X4 PHARMACEUTICALS INC. - COMMON STOCK

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

29 May 2024 15:30:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

13 May 2024 07:00:01 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

09 May 2024 05:30:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

07 May 2024 05:01:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 May 2024 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

30 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome

29 Apr 2024 05:30:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

01 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

21 Mar 2024 05:01:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024

12 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

09 Dec 2023 11:00:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Dec 2023 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences

10 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates

09 Nov 2023 05:01:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report Third-Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 9, 2023

02 Nov 2023 07:00:01 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome

31 Oct 2023 07:00:13 By Nasdaq GlobeNewswire